Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

Therapeutic Advances in Medical Oncology(2023)10.1177/17588359231198446Source: DataRank Database

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? is a research paper published in Therapeutic Advances in Medical Oncology (2023). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.14)OA: goldTopics (26)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Jacobi Hines ORCID,Valter Torri ORCID,Luca Porcu ORCID,Jessica Donington ORCID,Christine M. Bestvina ORCID

Live enrichment

PubMed:37720499 PMC:PMC10504845 OpenAlex:https://openalex.org/W4386767057

National Institutes of Health

Grant: T32 GM07019

NIGMS NIH HHS

Grant: T32 GM007019

National Institutes of Health

Grant: 5T32GM007019-13

CLINICAL THERAPEUTICS

FWCI

1.14

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc

journalhttps://journals.sagepub.com/doi/pdf/10.1177/17588359231198446

publisherhttps://journals.sagepub.com/doi/full-xml/10.1177/17588359231198446

journalhttps://doi.org/10.1177/17588359231198446

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37720499

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10504845

Fields of Study

Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations03 medical and health sciences0302 clinical medicine

Keywords

MedicineSurrogate endpointClinical endpointClinical trialOncologyNeoadjuvant therapyPerioperativeLung cancerInternal medicineBreast cancerCancerStage (stratigraphy)SurgeryImmunotherapyNeoadjuvantEndpointsChemoimmunotherapyPathologic ResponseNeoplasms. Tumors. Oncology. Including cancer and carcinogensReviewRC254-282

Sustainable Development Goals

SDG 0: Good health and well-being

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

FAIR Checklist

Authors (10)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)